VJHemOnc is committed to improving our service to you

EBMT 2020 | EBV-LMP2-specific TCR for EBV associated malignancies

VJHemOnc is committed to improving our service to you

Wesley Huisman

Wesley Huisman, MSc, Leiden University Medical Center, Leiden, The Netherlands, discusses his abstract on the development of the first functional human leukocyte antigen (HLA) 01-restricted Epstein-Barr virus latent membrane protein 2 specific (EBV-LMP2-specific) T-cell receptors (TCR) for TCR gene therapies for EBV associated malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter